Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Cost of Revenue (2016 - 2017)

Lisata Therapeutics (LSTA) has disclosed Cost of Revenue for 8 consecutive years, with $8.0 million as the latest value for Q1 2017.

  • For the quarter ending Q1 2017, Cost of Revenue rose 29.13% year-over-year to $8.0 million, compared with a TTM value of $33.0 million through Mar 2017, up 43.15%, and an annual FY2016 reading of $31.1 million, up 54.45% over the prior year.
  • Cost of Revenue was $8.0 million for Q1 2017 at Lisata Therapeutics, down from $9.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $9.2 million in Q4 2016 and bottomed at $2.4 million in Q1 2013.
  • Average Cost of Revenue over 5 years is $5.2 million, with a median of $4.2 million recorded in 2013.
  • The sharpest move saw Cost of Revenue fell 20.59% in 2013, then surged 84.89% in 2016.
  • Year by year, Cost of Revenue stood at $3.3 million in 2013, then rose by 24.49% to $4.2 million in 2014, then skyrocketed by 48.5% to $6.2 million in 2015, then soared by 49.53% to $9.2 million in 2016, then dropped by 13.01% to $8.0 million in 2017.
  • Business Quant data shows Cost of Revenue for LSTA at $8.0 million in Q1 2017, $9.2 million in Q4 2016, and $8.6 million in Q3 2016.